Expressive language and social communication abilities in children with spinal muscular atrophy type 1.
Chiara Brusa, Bianca Buchignani, Chiara Cutri and 9 others
PMID 40910950WHAT IT FOUND
Children with later-onset SMA type 1 said far more words than those with early onset.
Four of 37 screened positive for autism traits, but many parents could not answer questions because motor impairments blocked the behaviours the test asks about.
Key findings
01Children with SMA1c had a median of 298 words produced versus 4 for SMA1b.
02Four of 37 participants scored at or above the autism screening cut-off, suggesting need for further assessment.
03Twenty-one of 37 parents could not answer one or more social communication questions because their child was non-verbal or too weak to perform the required actions.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study was a feasibility pilot with a very small sample size (15 for language, 37 for social communication), limiting generalisability. The MB-CDI was administered to children older than the validated age range, making comparison to population norms impossible. The SCQ is not standardised for children with severe motor impairments, leading to a high rate of unanswered questions (21 of 37 parents) and potential misinterpretation of motor deficits as social communication issues. There was no control group of typically developing children or children with other neuromuscular conditions. The cross-sectional design means the study captures a single point in time rather than tracking development over time.
Declared interests
Funding was provided by SMA REACH UK, Biogen, Muscular Dystrophy UK, the MRC Translational Research Centre, and the NIHR Biomedical Research Centre. Several authors reported conflicts of interest, including advisory board participation, speaker fees, and clinical trial involvement with Biogen, Roche, Novartis, and other pharmaceutical companies manufacturing SMA treatments.
The easy way to misread this
Do not interpret a low SCQ score or an inability to answer SCQ items as evidence of autism or social communication disorder. The tool is not validated for children with SMA1, and many items require motor or verbal abilities that these children physically lack. A positive screen or missing data should prompt a comprehensive, standardised assessment by a specialist, not a diagnosis based on the questionnaire alone.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →